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0.8%), TVR (3.9 vs 2.8%), death (2.2 vs 2.8%), and MACE (6.1 vs 5.7%) as those with- 
out prior angina (P=NS for all). Further, during 1-year follow-up, no difference was found 
in the incidence of death (4.7 vs 5.6%, p=0.60) or MACE (23 vs 17%, p=0.07), between 
patients with and those without prior angina. 
Conclusions: A history of angina prior to acute myocardial infarction does not confer 
protection from adverse outcomes in patients undergoing primary angioplasty. Our find- 
ings challenge the clinical relevance of ischamic pre-conditioning in such patients. 
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1101-33 Characteristics and Outcome of Patients With ST 
Elevation Versus Non-ST Elevation Myocardial 
Infarction: Results of the MONICA Augsburg Myocardial 
Infarction Registry 1985-1995 
Bernhard Kuch, Heinz D. Bolte, Wolfgang von Scheidt, Hannelore L5wal, L Medizinische 
Klinik, Klinikum Augsburg, Augsburg, Germany, GSF-Forschungsinstitut, Neuherherg, 
Germany. 
Background: The classification of myocardial infarction (MI) has been more and more 
moved from discerning Q-wave from Non-Q-wave MI to classifying MI by ST- wave 
dynamics. Data about patient (pat.) characteristics and prognosis in relation to their ST- 
wave dynamics are scarce. Methods and Results: We, therefore, analyzed ECG-data 
(Minnesota-Coding) from the MONICA Augsburg Myocardial Infarction-Registry from 
1985-1995 (n= 2896; aged 25-75 years; 74% men). ST-Elevation MI (ST-E) was most 
frequent (59%), followed by MI with unspecific ST-changes (neither elevation or depres- 
sion; ST-U; 25%) and MI with ST-depression (ST-D; 16%). Pat. with ST-D were more 
often diabetics than pat. with ST-E or ST-U (28.1 vs. 21.9 and 20.5%; respectively), ware 
more often female (31.5 vs. 26.3 and 19.7%), had more often a history of angina (47.3 
vs. 36.7 and 40.0%) and previous MI (27.6 vs. 19.5 and 23.9%), and were less often 
treated by thrombolytics (13.6 vs. 38.8 and 12.4%; p for all comparisons < 0.001). In 
addition, pat. with ST-D were significantly older, had a higher mean pulse rate during 
admission, and a lower peak CK level than pat. with ST-E (p <0.01 respectively). The 28- 
day-case fatality-rate was 13.2% for ST-D, 10.8% for ST-E, and 7.5% for ST-U, respec- 
tivety (significance only for ST-E vs. ST-U; p < 0.001; for ST-E vs. ST-D p > 1). These 
case-fatality differences were not altered substantially by multivariate testing in a logistic 
regression model including the above mentioned ifferences in history and therapy. 
Conclusion: 25% of MI-pat. had a non-diagnostic ECG. This group has the lowest mortal- 
ity. Despite significant differences in presentation and cardiovascular isk-factor history, 
pat. with ST-elevation did not differ in terms of short-term prognosis from pat. with ST- 
depression. 
1101-34 Opportunities for Enhancing the Use of Evidence-Based 
Medicines for Acute Coronary Syndromes: Insights 
From the SYMPHONY Studies 
Judith Kramer. L. Kristin Newby, John Simes, Frans Van de Weft, Christopher Granger, 
Kerry Lee, Manjushri Bhapkar, Robert Califf, Paul W. Armstrong, University of Alberta, 
Edmonton, Alberta, Canada, Duke Clinical Research Institute, Durham, North Carolina. 
The extent to which evidence-basad therapy [Class IA or IB evidence (AHNACC 9/2000 
and ESC 9/2000)] is applied internationally to the broad cross-section of patients early 
after acute coronary syndromes (ACS) is unknown. Accordingly, we evaluated this issue 
in 15,904 patients from 36 countries entered into the Symphony and 2nd Symphony 
studies of sibrafiban between Aug 1997 and Aug 1999. We analyzed by geographic 
region the use of concomitant medications between each patient's qualifying ACS event 
and start of study treatment [median 91 hrs); and to what extent international variations 
in treatment could be explained by differences in patient risk profile. The data are shown 
in the Table. 
There were important variations in evidence-based treatment of ACS across geographic 
region, which remained highly significant (p<0.001) after adjustment for all major patient 
risk factors for future coronary events. Given the greater use of some treatments but 
lesser use of others within the same region, we believe these findings are unlikely to be 
driven by cost alone. Our data also indicate substantial global opportunities for improving 
secondary prevention. Hence continued monitoring of these international patterns of care 
and development of appropriate interventions to increase adherence to evidence-based 
~]uidelines i a desirable next step. 
Med Class Asia L.Amedca E.Europe W.Europe USA Canada Au/NZ 
n=551 n=557 n=2661 n=3431 n=7185 n=871 n=648 
ASA 87% 86% 75% 82% 85% 88% 91% 
Beta blockers 68% 75% 70% 69% 73% 78% 75% 
Lipid lowering 37% 17% 10% 30% 40% 29% 42% 
ACE inhibitors 56% 50% 48% 30% 33% 36% 33% 
Heparin 37% 61% 55% 52% 78% 79% 51% 
LMWH 27% 16% 28% 34% 10% 11% 34% 
ABSTRACTS - Myocard ia l  In fa rc t ion  and  I schemia  303A 
1101-35 Early Use of Glycoprotein 2b3a Inhibitors and 
Outcomes in Non-ST Elevation Mh Observations From 
the NRMI-4 
Eric D, Peterson, John G. Canto, Charles V. Pollack, Lori Parsons, Matt T. Roe, Kathee 
Littrell, Nathan R. Every, Hal V. Barron, for the NRMI-4 Investigators, Duke C/inica/ 
Research Institute, Durham, North Carolina. 
Background: The recent AHA/ACC ACS Guidelines recommend early use of glycopro- 
tein lib-Ilia inhibitors (GP 2b3a) in non-ST elevation MI (NSTEMI) patients, yet commu- 
nity adoption has been slow. 
Methods: We examined the relationship between "eady use" of GP 2b3a within 24hrs of 
admission and in-hospital mortality in 32,710 NSTEMI patients eligible for GP 263a, 
treated at 1,087 hospitals in the NRMI 4 Registry between July 2000-April 2001. 
Results: Overall, 24% of eligible NSTEMI patients were begun on a GP 2b3a in <24hrs. 
Patients treated with GP 2b3a <24 hrs were younger, more likely male, and had chest 
pain and ST depression on presentation than those not. Unadjusted in-hospital mortality 
rate was significantly lower in those treated with GP 2b3a <24hrs than those not treated 
early (3.2% vs 8.5%, p<0.0001). After adjusting for 13 patient risk factors (NRMI NSTEMI 
risk model, C-index 0.75), and for hospital size, region, teaching affiliation and cath facili- 
ties, patients getting GP 2b3a <24 hrs had 32% lower relative risk for in-hospital mortality 
(adjusted OR 0.68, 95% CI 0.59-0.79). Adjustment for treatment propensity (to receive 
GP 2b3a<24 hrs) revealed similar results. The Figure displays mortality rates by GP2b3a 
use <24hrs according to NRMI risk group. 
Conclusion: Early use of GP 2b3a within 24 hrs of admission was associated with lower 
in-hospital mortality across the NSTEMI risk spectrum. As only 24% of eligible patients 
received early GP2b3a therapy, there is considerable room for quality improvement. 
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1101-36 Comparison of Characteristics, Treatment, and 
Outcomes of Patients Enrolled Versus Not Enrolled in a 
Clinical Trial: Findings From TIMI 9 Registry and 9B 
Trial 
Maria Cecilia Bahit, Elliott M. Antman, Sabina A. Murphy, Carolyn H. McCabe, 
Christopher P. Cannon, Brigham and Women's Hospital, Boston, Massachusetts. 
Background: Because mortality in clinical trials (CT) is generally lower than in registries 
of clinical practice, it has been suspected that patients are lower risk. However, little is 
known about the characteristics of patients included vs. not in CT. Methods: To address 
this issue, TIMI 9 Registry prospectively evaluated characteristics and in-hospital out- 
comes for ST-elevation MI patients at 20 hospitals during the conduct of TIMI 9B trial.We 
compared characteristics, treatment and outcomes of patients in TIMI 9B trial (N=3002), 
with others eligible for thrombotysis but not enrolled in the TIMI 9B thai (N=296), and with 
those not-eligible for thrombolysis by ACC/AHA criteria at the same centers (N=282). 
Results: At TIMI 9 Registry hospitals, 46% of eligible patients were enrolled in TIMI 9B. 
Across the three groups, a gradient of both high-risk baseline characteristics, use of rep- 
effusion therapy and mortality was observed. In addition, although we did not assess 
contraindications for each medication, use of aspirin, (and beta-blockers, ACE inhibitors) 
both initially and at discharge was lower among eligible/not enrolled patients (p<0.0001 
for aspirin) or ineligible patients.(Tabla) 
Conclualon: In this prospective registry, we found that half of eligible patients were 
enrolled. Those not enrolled had higher risk characteristics and worse outcomes; how- 
ever, they also were treated less frequently with guideline-recommended medications, 
which may have contributed to their hi~lher mortality. 
Eligible/ Eligible/not Not eligible/ 3-way p 
enrolled enrolled not enrolled 
Age (years) 60.1 ± 11.9 62.3 ± 13.5 67.5 ± 12.6 <0.0001 
Female gender 25.1% 32.4% 39.5% <0.0001 
Aspirin 99.4% 91.5% 75.2% <0.0001 
Thrombolysis 99.6% 59.8% 22.5% <0.0001 
Primary PCI 0 12.5% 12.7% <0.0001 
In hospital death 5.1% 8.4% 19.8% <0.0001 
Death + MI+ Shock+ severe CHF 9.0% 15.9% 30.1% <0.0001 
1101-37 Approach After Thrombolytic Therapy: Invasive Versus 
Conservative Management: Global Registry of Acute 
Coronary Events 
Immad Sadiq, Harold L Dauerman, Robert J. Goldberg, Warner Klein, David Briagsr, Ph. 
Gabriel Steg, Gilles Montalescot, Josd L6pez-Send6n, Andrzej Budaj, Joel M. Gore, for 
the GRACE Investigators, Saint Vincent Hospital & University of Massachusetts Medical 
School, Worcester, Massachusetts, Medizinische Universitdtsklinik, Graz, Austria. 
Background: Thrombolytics (lyrics) reduce mortality of patients (pts) with acute ST seg- 
ment elevation MI (STE MI). However, the impact of a subsequent invasive strategy on 
outcomes has not been studied in an international population-based setting. 
Methods: 1,766 pts enrolled in GRACE with STE MI who received lytics were divided into 
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3 groups based on receipt of cardiac catheterization (cath) < 12 hours of lytics (early 
cath,N=261), > 12h after lytics (late cath,N=451) or no cath (conservative treat- 
ment,N=1056). The likelihood of in-hospital mortality and reinfarction was determined 
using multivariate analysis. 
Results: 41% pts underwent cath during index hospitalization. 89% of eady cath pts had 
a PCI (pemutaneous coronary intervention) as opposed to 61% of the late cath group (p 
< 0.0001). The outcomes of the early cath group did not differ significantly from the lyrics 
only group. However, the incidence of in-hospital death was significantly lower in the late 
cath group as compared to the lytics only group (2% Versus 6.8%, p 0.0002). This 
remained true even after controlling for differences in baseline and in-hospital character° 
istics between the 2 groups (late oath mortality OR 0.3, 95%CI 0.13-0.63). The likelihood 
of a reinfarction was, however, significantly high in the late cath group. 
Conclusions: Although lytics substantially reduce mortality after an acute STE MI many 
pts may derive an additional benefit from the use of a cardiac cath and, if indicated, a 
PCI, especially if performed non-urgently. 
Odds of death and reinfarction during Index hospitalization 
(* compared with lytlcs only group) 
DEATH DEATH REINFARCTION REINFARCTION 
OR 95%CI OR 95%CI 
Late Cath 0.3 0.13-0.63 3.1 1.78-5.23 
Cath 0.5 0.27-0.79 2.5 1.49-4.25 
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822-1 Elevated White Blood Cell Count Is Associated With 
Higher Mortality in Patients With Acute Coronary 
Syndromes Independent of Other Cardiac Markers: A 
TACTICS - TIM118 Substudy 
Marc S. Sabatine. David A. Morrow, Sabina A. Murphy, Laura A. Demopoulos, Peter M. 
DiBattista, Carolyn H. McCabe, Christopher P. Cannon, Eugene Breunwald, Michael 
Gibson, Brigham and Women's Hospital, Boston, Massachusetts. 
Background & Methods: Higher white blood cell counts (WBCC) have been associated 
with higher mortality in the setting of acute coronary syndromes (ACS). We sought to 
examine if this relationship was true independent of other cardiac markers of inflamma- 
tion and/or infarction in TACTICS - TIM118. 
Results: The median WBCC (103/ram 3) at baseline was 8.1 [interquartile range (IR) 6.7- 
10.1]. Median WBCC was higher in patients who died by 30 days (9.1, IR 7.8-12 vs. 8.1, 
IR 6.6-10.1; p=0.0016) and 180 days (8.75, IR 7.6-10.95 vs. 8.1, IR 6.6-10.1; p=0.0047). 
Of the 1841 patients with WBCC & C-reactive protein (CRP) data, patients with a low 
WBCC (<25 th percentile) and a low CRP (<1.5 mg/dL) had a 6-month mortality rate of 
0,7%, those with a low CRP but a high WBCC had a rate of 2.8%, and those with a high 
CRP regardless of WBCC had a mortality rate of 6.2% (p<0.0001, Z 2 for trend). In a Cox 
proportional hazards model adjusted for age, smoking, craatinine, prior MI, prior aspirin 
use, troponin level, and ST deviation, patients with low CRP but high WBCC remained at 
significantly higher risk of death at 180 days [hazard ratio (HR) 5.4, p=0.02], and patients 
with high CRP were at even higher risk (HR 12.2, p=0.0007). 
Conclusion: Higher baseline WBCC are associated with a higher risk of 6-month mortal- 
ity. Even after adjusting for traditional risk factors, including troponin and ST deviation, 
assessment of two inflammatory markers, WBCC and CRP, can be used to stratify 
patients with ACS into low, intermediate, and high 6-month mortality risk. 
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822-2 Elevated C Reactive Protein (CRP) Is Associated With a 
Higher Risk of Thrombotic Occlusion and Poorer Flow 
Following Percutaneous Coronary Intervention in 
Patients With Acute Coronary Syndromes: A TACTICS 
TIM118 Angiographic Substudy 
Michael Gibson, David Morrow, Ralph Vicari, Graham Wong, Laura Demopoious, Peter 
DiBattista, Sabina A. Murphy, Chdstopher P. Cannon, Eugene Braunwald, Harvard 
Clinical Research Institute, Boston, Massachusetts, Brigham and Women's Hospital 
Boston, Massachusetts. 
Background & Methods: Higher CRP levels are associated with a higher risk of cardiac 
events. The relationship between baseline CRP and angiogrephic findings has not been 
explored. In the TACTICS / TIMI 18 trial of invasive versus conservative strategies in the 
management of ACS, we hypothesized that elevations in CRP would be associated with 
unfavorable angiogrephic findings such as a higher risk of thrombotic occlusion. Results: 
Patients with a closed artery (TIMI Flow Grade (TFG) 0/1) had higher CRPs than patients 
with an open artery (TFG 2/3) (1.98 _+ 2.7 mg/dL, n=63 vs 1.22 + 1.8 mg/dL, n=392, 
p=0.005), and conversely a CRP > 2X the threshold (> 3.0 mg/dL) was associated with a 
higher risk of thrombotic occlusion (26.8%, 15/56 vs 12.0%, 48/399 p=0.003). Likewise, 
an elevated CRP > 2X threshold was associated with higher (i.e, slower) Corrected TIMI 
Frame Counts (CTFCs) on diagnostic catheterization (58.2 + 36.6, median 45.3, n=41, 
vs 43.1 + 30.6, median 32, n= 341, p=0.037 comparing medians). Even among patients 
who were troponin negative, those pts with a closed artery had a higher CRP compared 
to those with an open artery (1.84 _+ 2.4, n=10 vs 0.78 + 1.5, n=156, p=0.04) and again a 
CRP > 2X the threshold was associated with a higher risk of thrombotic occlusion 
(30.0%, 3/10 vs 4.5%, 7/156 p=0.001 ). Pts. who did not achieve TFG 3 following percuta- 
neous coronary intervention (PCI) had higher CRP levels (2.25 .t: 3.5 mg/dL, n=19 vs 
1.31 _+ 1.9 mg/dL, n=356, p=O.05), and likewise a CRP > 2X threshold tended to be asso- 
ciated with a lower incidence of TFG 3 after PCl (89.6%, 43/48, vs95.7%, 313/327, 
p=O.07). Those pts with no reflow or distal embolization during PCI had higher CRP lev- 
els (2.81 + 3.5, n=9 vs 1.33 + 2.0, n=367, p=0.034). There was no association between 
CRP and either disease extent (1,2,3 vessel disease) or tissue level perfusion as 
assessed using the TIMI Myocardial Perfusion Grade. Conclusions: Higher baseline 
CRP values are associated with a higher risk of thrombotic vessel occlusion on diagnos- 
tic cardiac catheterization and a lower incidence of TIMI 3 Flow after PCI. 
2:30 p.m. 
822-3 Ef fect  o f  A torvasts t in  on C-React ive Prote in in Patients 
With Acute Coronary Syndromes: A Substudy of the 
MIRACL Trial 
Scott Kinlav. Neder Rifai, Peter Libby, Peter Ganz on behalf of the MIRACL Investigators, 
Brigham and Women's Hospital Boston, Massachusetts, Children's Hospital Boston, 
Boston, Massachusetts. 
Background: Coronary lesions of patients with acute coronary syndromes are charac- 
terized by intense inflammation. The MIRACL trial showed that atorvastatin 80 mg/day 
reduced recurrent ischemic events in the first 16 weeks. The purpose of this study was to 
determine whether intensive lipid lowering can reduce serum C-reactive protein (CRP), a 
marker of inflammation, in patients with unstable angina or non-Q-wave MI. Methods: 
Blood samples were collected at baseline and at 16 weeks from 2,322 of 3,086 patients 
participating in the MIRACL trial. C-reactive protein (CRP) was measured by a highly 
sensitive immunoassay. The change in CRP was compared between patients randomly 
assigned to atorvastatin vs. placebo. The change in CRP was also evaluated separately 
in patients with unstable angina and non-Q-wave myocardial infarction. Results: The 
baseline median CRP was similar in the patients assigned to atorvastatin (10.0 mg/L) 
and placebo (9.9 mg/L), (p=NS). The reduction in CRP over 16 weeks of treatment was 
significantly greater in patients on atorvastatin (-7.5 mg/L) compared to placebo (-6.0 mg/ 
L, p<0.001). Atorvastatin led to a greater reduction in CRP in patients with non-Q-wave 
MI (-15.9 vs -10.0 mg/L, atorvastatin vs. placebo, p=0.011), as well as in patients with the 
unstable angina (-3.5 vs -2.5 rag/L, atorvastatin vs. placebo, p=0.003). Conclusion: 
Atorvastatin (80mg/day) reduced CRP, a marker of inflammation, in patients with acute 
coronary syndromes. This was observed in patients with non-Q-wave MI as well as 
unstable angina. Thus, in patients with acute coronary syndromes, atorvastatin reduces 
inflammation, a mechanism associated with plaque stabilization. This effect may contrib- 
ute to the clinical benefit observed in the MIRACL trial. 
2:45 p.m. 
822-4 Detection of Cardiac Neurohormonal Activation 
Complements Cardiac Troponin for Predicting 
Recurrent Events in UA/NSTEMh Prognostic Utility of 
BNP in TACTICS-TIM118 
David A. Morrow. James A. de Lemos, Marc S. Sabatine, Sabine A. Murphy, Peter M. 
DiBattiste, Carolyn H. McCabe, Christopher P. Cannon, Eugene Braunwald, Brigham & 
Women's Hospital Boston, Massachusetts. 
B-type natriuretic peptide (BNP) is released in response to increased ventdcular wall 
stress. Recent findings indicate that plasma levels of BNP predict mortality among 
patients (pts) with unstable angina & non-ST elevation MI. However, data in this popula- 
tion, and in combination with cardiac troponins are few. METHODS: Baseline levels of 
BNP (Biosite Diagnostics) and cTnl (Bayer Diagnostics) were available for 1541 pts with 
non-ST elevation ACS randomized to early invasive(INV) vs. conservative(CONS) man- 
